Gabrielle Pedroso da Silva¹, Leonardo Pizol Ferreira¹, Gustavo Elias Arten Isaac² and Renan Marcel Bonilha Dezena^3,4*

¹University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Department of Pharmaceutical Science, Brazil

*Corresponding Author: Renan Marcel Bonilha Dezena, University Center of the Octávio Bastos Teaching Foundation (UNIFEOB), Faculty of Pharmacy, Expert Collaborator and Preformulation Specialist in The Pharmaceutical Industry, Brazil.

Received: January 19, 2023; Published: January 25, 2023

Abstract

Background

The understanding of how a chemical substance, used as a drug, exerts its activity within the body, it must be taken into account that the three-dimensional structure of this drug has fundamental importance in the biological receptor, because the format of a drug molecule must be complementary to its receptor site, just as a key is complementary to the lock,  so that, through chemical bonds, they bind properly and generate the expected biological response [1,2].

References

1. Mansour MA., et al. “Highlights on selected growth factors and their receptors as promising anticancer drug targets”. The International Journal of Biochemistry and Cell Biology 140 (2021): 1060-1087.
2. Tripathi A and Bankaitis VA. “Molecular Docking: From Lock and Key to Combination Lock”. Journal of Molecular Medicine and Clinical Applications 1 (2017): 1-19.
3. Naveen Chhabra., et al. “A review of drug isomerism and its significance”. International Journal of Applied and Basic Medical Research 1 (2013): 16-18.
4. Brooks WH., et al. “The significance of chirality in drug design and development”. Current Topics in Medicinal Chemistry 7 (2011): 760-770.
5. Atkins P., et al. “Chemical Principles: The Quest For Insight”. Bookman Editorial (2018).
6. Katzung BG and Trevor AJ. “Basic and Clinical Pharmacology”. Lange Medical Publications (2017).
7. Roberts JS., et al. “R-etodolac is a more potent Wnt signaling inhibitor than enantiomer, S-etodolac”. Biochemistry and Biophysics Reports 30 (2022): 1-6.
8. Benez FHN., et al. “Comparative study of anti-inflammatory, ulcerogenic and cytotoxic activities of racemate and S-ibuprofen”. Journal of Basic and Applied Pharmaceutical Sciences 3 (2013): 327-332.
9. Dalal J., et al. “S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine”. International Journal of Hypertension 2018 (2018): 1-14.
10. Papp LA., et al. “Determination of Chiral Impurity of Naproxen in Different Pharmaceutical Formulations Using Polysaccharide-Based Stationary Phases in Reversed-Phased Mode”. Molecules 9 (2022): 1-13.
11. Estrada-Valenzuela D., et al. “Lipase Assisted (S)-Ketoprofen Resolution from Commercially Available Racemic Mixture”. Pharma 10 (2021): 1-10.
12. Pandya PA., et al. “Simultaneous enantioseparation and simulation studies of atenolol, metoprolol and propranolol on Chiralpak® IG column using supercritical fluid chromatography”. Journal of Pharmaceutical Analysis 6 (2021): 746-756.
13. Harvison PJ. “Warfarin”. xPharm: The Compr. Pharmacol. Ref. (2007): 1-7.
14. Passie T., et al. “Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers”. European Neuropsychopharmacology 44 (2021): 92-104.

Citation

Citation: Renan Marcel Bonilha Dezena., et al. “Asymmetry Synthesis: Powerful Tool for The Pharmaceutical Industry". Acta Scientific Microbiology 6.2 (2023): 100-102.

Copyright

Copyright: © 2022 Renan Marcel Bonilha Dezena., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.